Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter.